Gubra (GUBRA) Investor presentation summary

Strategic positioning and business model

• Operates as a disease-agnostic techbio with deep peptide and preclinical expertise, leveraging AI-driven drug discovery and specialized CRO services.

• Business model integrates Biotech, CRO, and Ventures units, with a focus on high-value peptide assets and lean, asset-centric spin-outs.

• Maintains a strong commitment to sustainability, investing 10% of pre-tax profit in related initiatives.

• CRO business serves 16 of the top 20 global pharma companies and specializes in high-growth disease areas.

• 3D imaging and AI analytics differentiate preclinical research capabilities, enabling high-throughput, organ-agnostic analysis.

Pipeline and scientific innovation

• Pipeline includes multiple high-value assets in obesity, cachexia, rare diseases, and muscle wasting, with strong partnering capabilities.

• Three potential obesity blockbusters: ABBV-295 (long-acting amylin analog), BI 3034701 (triple agonist), and GUB-UCN2 (novel mechanism for muscle preservation and fat loss).

• UCN2 program targets high-quality weight loss, increasing muscle mass and reducing fat, with additional cardiac and metabolic benefits.

• GUB-UCN2 entering first-in-human trials in H1 2026, with broad indication expansion potential.

• AI-driven StreamLine platform enables rapid peptide candidate identification, delivering assets with blockbuster potential in under 1.5 years.

Key partnerships and deals

• Landmark $2.2bn out-licensing deal with AbbVie for ABBV-295, including $350m upfront payment and future royalties.

• BI 3034701 triple agonist partnered with Boehringer Ingelheim, entering Phase 2 in 2026.

• PTH analog collaboration with Camurus and additional partnerships with Amylyx and Hemab in rare diseases.